Establishment Labs’ Breast Augmentation Tech Debuts in Brazil

Establishment Labs Holdings Inc. has launched Preservé in Brazil, the first country in its global rollout. Preservé is the second product in the company’s minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech.

“These are not small innovations, this is an entirely new era for aesthetic breast surgery,” Establishment Labs Founder/CEO Juan José Chacón-Quirós said. “Whereas Mia made minimally invasive breast aesthetics possible for women looking for a one to two cup enhancement, Preservé allows less invasive breast surgery for the day-to-day breast augmentation patient.”

Preservé is designed to preserve breast tissue during aesthetic breast surgery, maintaining the breast’s structural anatomy and function for more stable and natural outcomes when compared to traditional breast augmentation. Preservé leverages Establishment Labs’ proprietary minimally invasive surgical tools coupled with the Ergonomix2 implants, which feature the patented SmoothSilk surface, designed for enhanced biocompatibility and softness, and which are unique in the industry as their shape adapts as the body changes position, according to the company. Preservé is intended for primary augmentations up to four cups, hybrid augmentations, and mastopexy augmentations.

“Historically, many women have not been convinced by traditional methods and legacy techniques,” Chacón-Quirós continued. “With Mia and Preservé, we have solutions that address these concerns. The technology platform of breast tissue preservation allows plastic surgeons to create natural results with less disruption of the patient’s breast tissue. By improving safety profiles, recovery times, and achieving the breast aesthetic patients are looking for, breast augmentation may now be possible for women that otherwise never would have considered it—as well as making the decision easier for many who were already considering. After Brazil, Preservé will rollout globally over the next few years, and this should contribute to top line growth and profitability.”

The company plans additional launches of Preservé this year worldwide. The medical devices used in Preservé, however, are not yet approved for commercial distribution in the United States.

“Breast tissue preservation is a new paradigm in breast aesthetics. With less invasive breast procedures made possible by technology pioneered by Establishment Labs, we can address many of the complications that lead to reoperations,” said Dr Kamakshi Zeidler, a San Francisco plastic surgeon and head of the Femtech board of Establishment Labs. “Preservé is an incredible new choice for women considering breast augmentation because it speaks to many of their aspirations, including smaller scars, quicker recovery, maintaining breast sensation, and avoiding unnecessary reoperations.”

Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers solutions for breast health, breast aesthetics, and breast reconstruction in more than 90 countries; over 4 million Motiva devices have been delivered to plastic and reconstructive surgeons since 2010. Establishment Labs’ minimally invasive platform consists of Mia Femtech, a minimally invasive experience for breast harmonization, and Preservé, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation, and mastopexy augmentation. GEM is a next-generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora tissue expander is used to improve outcomes in breast reconstruction following breast cancer and reportedly is the world’s only regulatory-approved expander with an integrated port using radio-frequency technology that is MRI conditional. Zensor is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by more than 200 patents applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and U.S. Food and Drug Administration 21 CFR 820.